What Gelaspon Treats: Main Uses and Benefits

The Gelaspon product line is generally used to address conditions presenting with systemic or localized discomfort through its two distinct forms: the stabilization of fluid volume and the local management of bleeding.

---

Addressing Acute Circulatory Stress and Volume Deficit

The Gelaspan Infusion is primarily applied in clinical settings to manage hypovolaemia, a condition marked by increased physiological stress due to significant fluid loss, and the immediate signs of shock. It is relevant for easing symptoms related to systemic imbalance, such as low blood pressure (hypotension), which can arise from trauma or surgery. The therapeutic benefit supports the maintenance of systemic balance and supports circulatory function, which supports general well-being during symptomatic phases. Indications commonly used across conditions presenting with acute episodes include those involving hypovolaemia, hypotension, and shock due to blood or fluid loss.

“The primary benefit provides support in contexts involving heightened systemic burden.”

Quick Fact: Relief for Systemic Imbalance

---

Localized Bleeding Control in Surgical Wounds

The Gelaspon Strip is relevant in situations requiring effective local hemostasis, and is applied across domains where additional symptomatic support is needed. It is commonly used as an adjunct in various surgical settings, including routine dental extractions and general operative procedures, to manage capillary, venous, or small arteriolar bleeding where traditional methods are not sufficient. The primary benefit contributes to easing the overall symptom load by supporting local hemostasis, leading to supportive local bleeding control at the wound site, which assists with maintaining functional stability during operative procedures.

The Gelaspon brand covers two distinct medical products—a systemic Infusion and a local Absorbable Gelatin Sponge—each with unique regulatory eligibility rules based on official labeling.

Classification	Succinylated Gelatine Infusion	Absorbable Gelatin Sponge
Populations for whom use is contraindicated	Hypersensitivity to gelatin or red meat/offal; Hypervolaemia; Hyperhydration; Acute congestive cardiac failure.	Known allergies to porcine collagen; Intravascular compartments; Closure of skin incisions.
Age-related eligibility rules	Children: Safety and efficacy not yet completely established. Older Adults: Caution advised due to risk of cardiac or renal insufficiency.	Generally permitted in adults and children for surgical use.
Condition-specific eligibility rules	Severe hypernatraemia/hyperchloraemia, severe impaired renal function, or major blood coagulation disorders require caution.	No systemic condition-specific rules apply.
Pregnancy and lactation eligibility status	Pregnancy: Restricted to emergency situations only. Lactation: Insufficient data; risk to infant cannot be excluded.	No explicit restrictions documented in official labeling.

Official regulatory documents define non-eligibility by establishing two sets of constraints: the systemic Infusion is prohibited in patients with pre-existing fluid overload or severe cardiac issues, while the local Sponge is restricted based on material allergy and specific, non-eligible application sites, such as inside blood vessels or on skin closures.

The official regulatory profile for Gelaspon addresses two distinct products—the intravenous solution (Infusion) and the absorbable gelatin sponge (Sponge)—each having unique interaction constraints.

Infusion (Succinylated Gelatine)

Interacting Medicines and Mechanisms

Co-administration of the Infusion with medicines known to cause sodium retention, such as corticosteroids and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), is a documented pharmacodynamic interaction that may compound the risk of oedema (fluid retention) [HPRA SmPC].

Infusion of large volumes results in a physiological dilution effect on endogenous coagulation factors. This effect, stated in labeling, can lead to the prolongation of blood clotting measurements, specifically Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT) [HPRA SmPC]. Caution is also advised when the Infusion is administered with medicinal products that may increase serum potassium, such as ACE inhibitors or potassium-sparing diuretics [Gelaspan 4% B.Braun].

Substance-Related Contraindication

The Infusion is formally contraindicated if the patient has a history of allergy to red meat or offal, or to the galactose-α-1,3-galactose (alpha-Gal) antigen, due to a highly increased risk of a severe anaphylactic reaction caused by cross-reactions with gelatin [HPRA SmPC].

Procedural and Test Constraints

• The Infusion must not be co-infused with blood or blood products through the same intravenous line [Gelaspan 4% B.Braun].
• The Infusion is known to interfere with laboratory tests, potentially causing falsely high values for certain results, including the erythrocyte sedimentation rate and unspecific protein assays [HPRA SmPC].

Sponge (Absorbable Gelatine)

Co-Administration Restrictions

The Sponge has documented restrictions for local use, with regulatory labeling stating that co-administration with other agents has not been evaluated for safety. The combination with topical thrombin is not recommended, and the Sponge should not be used in conjunction with methyl-methacrylate adhesives or certain other surgical agents [FDA Labeling (GELFOAM)].

How Gelaspon Works: Mechanism of Action

---

Physical Scaffolding for Accelerated Clot Formation

Gelaspon's primary mechanism is physical and local: the porous gelatin sponge acts as a structural scaffold, immediately absorbing blood and concentrating platelets and coagulation factors at the application site. This high-surface area provides the necessary physical substrate to accelerate the initial steps of the intrinsic clotting pathway, leading to the rapid formation of a stable, mechanical hemostatic plug, which facilitates the cessation of blood flow from small vessels.

---

Localized Modulation of the Coagulation Cascade

The structural presence of Gelaspon directly facilitates the contact activation of the coagulation cascade, specifically driving the conversion of fibrinogen into a fibrin mesh within its matrix. This localized, targeted influence on the final common pathway reinforces the clot, ensuring stability and contributing to a swift, localized limitation of hemorrhage at the site of application.

---

Peripheral Action and In Situ Biological Resorption

The action of Gelaspon is strictly peripheral (local) and does not exert systemic effects on the body's overall clotting function. Once its hemostatic function is complete, the gelatin matrix is safely broken down by the body's own enzymatic and cellular processes over several weeks. This biological resorption mechanism facilitates the material's clearance, allowing for the subsequent unimpeded continuation of the tissue repair sequence.

The administration of Gelaspon is formally structured around two distinct products with opposing routes and official usage patterns: the systemic Succinylated Gelatine Infusion (Gelaspan) and the localized Absorbable Gelatin Sponge (Gelaspon Strip). This usage is structured according to established clinical guidelines.

---

Official Administration Guidelines

Feature	Succinylated Gelatine Infusion (Volume Expander)	Absorbable Gelatin Sponge (Hemostatic Agent)
Route of Administration	Intravenous (IV) Infusion	Topical application to the bleeding surface
Dosing Schedule	Individualized; average initial dose is 500 to 1000 mL. Total volume is guided by the patient’s circulatory status, avoiding critical haemodilution.	Qualitative dose: Use only the minimum amount necessary to achieve hemostasis.
Preparation Requirements	Must be clear and can be warmed up to 37°C for rapid administration. The solution must not be infused concurrently with blood.	May be used dry or saturated with sterile saline or thrombin solution. Excess product must be removed from surgical cavities once bleeding is controlled.
Age-Group Rules	Contraindicated in children under 1 year of age; safety and efficacy are not fully established in older children.	Safety and effectiveness have not been established in children.
Procedural Conditions	The first 20 to 30 mL must be infused slowly for patient observation. In acute loss, the infusion can be administered rapidly in a matter of minutes.	Designed for single, adjunctive application. The product is absorbed by the body over 4 to 6 weeks in soft tissues, or within days on mucosal surfaces.

---

The official protocol requires distinct procedural steps for each product. The infusion necessitates careful, continuous monitoring and rate adjustments, while the sponge requires meticulous preparation, sterile placement, and subsequent removal of any material in excess of what is required to stop the bleeding, particularly from closed spaces.

Research Evidence / Overview of Studies for Gelaspon

Evidence for Intravenous Use in Acute Volume Deficit

Research has explored the Gelaspan Infusion in contexts where plasma volume replacement is studied, such as for acute hypovolemia or shock. The evidence landscape primarily consists of Randomized Controlled Trials (RCTs) and meta-analyses that compare the succinylated gelatine solution against other common intravenous fluids. These studies were conducted in populations that included surgical and trauma patients with acute blood loss.

Researchers focused on measuring outcomes related to systemic or functional imbalance, such as the duration of blood volume expansion and patterns of circulatory function. Findings reported that the solution was observed in studies to be associated with measurements of volume change immediately following infusion. When comparing the infusion to other fluids, research reports described patterns of comparative measurements for blood transfusion requirements, and findings regarding outcomes like mortality and kidney function have been mixed.

---

Evidence for Local Use in Surgical Bleeding

The Gelaspon Strip/Sponge, a topical product, was studied for its function as a physical adjunct in studies of localized hemostasis during surgical procedures. The research base involves controlled clinical studies that explored the use of the sponge in various operative settings, including dental extractions and procedures involving cancellous bone.

The primary outcomes describing episodic or acute changes that research examined involved measuring the time to hemostasis (how quickly bleeding stopped) and assessing postoperative wound healing. Studies also described the product's biocompatibility with local tissues.

---

What Research Gaps and Uncertainties Remain

For the Infusion, the certainty remains low for some critical comparative endpoints. The comparative evidence is lacking for many non-major outcomes, and studies monitoring long-term effects are limited, meaning those effects are not fully established. Research into its use in complex environments, such as critical care, often involves modest sample sizes, and data for certain groups, such as children, remain insufficient. The existing studies focus narrowly on its short-term function.

Key Studies & References

1. Benefits and risks of using gelatin solution as a plasma expander for perioperative and critically ill patients: a meta-analysis
2. GEL-FLOW® (absorbable gelatin powder) Safety Information and Clinical Studies (Pfizer)

Common questions about Gelaspon (FAQ)

Q: What does 'plasma volume substitute' mean in simple terms?

A: A plasma volume substitute is a medication used to restore circulating fluid in the bloodstream after acute loss. Its official purpose is to manage acute fluid deficit, such as hypovolaemia or shock, by replacing lost volume to support the patient's stable circulation.

Q: Is Gelaspon a type of blood product or a blood transfusion substitute?

A: Official documents classify the Infusion as a colloidal plasma volume substitute, not a blood product. Because of this distinction, regulatory guidelines specify that the Infusion is required not to be administered concurrently with blood or blood products through the same intravenous line.

Q: Is Gelaspon safe for children, or is it only for adults?

A: According to regulatory guidelines, the Infusion is formally prohibited for use in children under 1 year of age. For children older than 1 year, official information indicates that the safety and effectiveness are described as not yet fully established.

Q: What is the role of the 'balanced electrolyte solution' in Gelaspon IV?

A: The Infusion is prepared as a colloid solution suspended in a fully balanced electrolyte solution. This formulation is formulated to assist in maintaining fluid balance and is associated with a reduced trend toward acid-base changes, such as metabolic acidosis, compared to some other types of IV fluids.

Q: Is Gelaspon IV contraindicated if a patient has severe kidney disease?

A: Severe impaired kidney function is not listed as a formal contraindication for the Infusion. However, the official product information describes administration in patients who have severely impaired renal function as requiring caution.

Q: How long after the infusion starts does Gelaspon's effect on blood volume last?

A: Official data indicates that the duration of the blood volume expansion effect of the Infusion is approximately 3 to 4 hours. This duration is a factor in how its use is clinically determined during acute volume loss.

Q: Why does the packaging say the Gelaspon infusion must be clear and particle-free before use?

A: The official guidelines state that the infusion is required to be visually inspected to be clear and free of particles. This is necessary to mitigate the risk of contamination and serious physical adverse effects, such as embolism, which are associated with the infusion of visible particles.

Q: Can Gelaspon be used on superficial cuts, or is it only for deep surgical bleeding?

A: The Gelaspon sponge is intended for use in surgical procedures as an adjunctive product to help stop bleeding. Official product information specifically states that the sponge is contraindicated in the closure of skin incisions.

Q: Is Gelaspon the same as the product called Gelfoam?

A: The absorbable gelatin sponge is a product that belongs to the same pharmacological class (haemostyptic agent) as Gelfoam. Official regulatory documents for the Gelaspon sponge frequently cite Gelfoam regulatory labels as a source of clinical guidance.

Q: Why does Gelaspon require careful monitoring of electrolytes and fluid balance?

A: Monitoring is necessary to check for signs of circulatory overload, which is noted as a safety concern. Careful clinical monitoring of the patient's status is also described as being necessary to check serum electrolyte concentrations, acid-base balance, and blood coagulation status in at-risk individuals.

Q: Is Gelaspon used for anything other than major blood loss or shock?

A: The emergency treatment of manifest blood loss or shock is a key indication for the Infusion. However, the indications also include prophylaxis (prevention) of imminent hypovolaemia and shock.

Q: What are the signs of a non-severe allergic reaction to Gelaspon that I should know about?

A: Regulatory documents describe mild anaphylactoid reactions that may occur. These can include signs such as generalised redness (erythema), the appearance of hives (urticaria), or temporary swelling around the eyes (periorbital oedema).

Q: Is it normal to have a mild, temporary fever after receiving Gelaspon?

A: Fever and chills are listed in official regulatory documents as a very rare undesirable effect associated with the Infusion.

Q: Does Gelaspon Infusion affect a person's ability to drive or use machines?

A: The product labeling for the Infusion states that no relevant effect has been observed on a person's ability to drive or use machines.

Q: What does the research say about Gelaspon's effects on the patient's base excess or chloride levels?

A: Studies comparing the balanced fluid solution (the Infusion) to standard saline indicate patterns of benefit in maintaining the body's electrolyte parameters. The balanced formulation is associated with a reduced trend toward hyperchloremic metabolic acidosis, a type of acid-base imbalance.

Q: Is the use of Gelaspon IV restricted to emergency room or operating room settings?

A: Administration of the Infusion is not restricted solely to emergency or operating room settings. However, it is required to occur wherever the necessary continuous and careful monitoring of the patient's circulatory status and fluid balance can be ensured.

Q: Are the electrolytes in Gelaspon IV different from those in standard saline solution?

A: Unlike standard saline solution, the Infusion is a fully balanced electrolyte solution. It contains essential salts such as potassium, calcium, and magnesium, which is associated with assisting the prevention of certain fluid and electrolyte imbalances in the body.

Q: What is the difference between Gelaspon and other colloid volume expanders?

A: Compared to other colloid volume expanders, official research notes that gelatins (like the Infusion) are described as having the shortest duration of plasma volume expansion. They are also associated with reports of a higher incidence of anaphylactoid reactions compared to natural colloids like albumin.

Storage and Disposal Requirements for Gelaspon

Official regulatory documents define specific storage and disposal rules for Gelaspon, which differ slightly between the Infusion solution and the Absorbable Strip/Sponge.

---

Storage Conditions

Product Form	Temperature & Environment	Packaging & Handling
Infusion Solution	Store below 25 C; Protect from light.	Keep in original outer carton; Use immediately after opening; Do not freeze.
Strip/Sponge	Store at room temperature in a dry place.	Maintain sterile blister packaging; Do not freeze.

All forms must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Gelaspon must be disposed of according to local requirements and regulatory guidelines. The product must not be thrown away via wastewater; patients should consult a pharmacist for official disposal methods.